Health Care · Surgical & Medical Instruments & Apparatus

GKOS GLAUKOS Corp SEC Filings & Insider Trading Activity 2026

company
CIK 1192448178 filings
Russell 2000

GKOS at a glance

GLAUKOS Corp (GKOS, SEC CIK 1192448) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on October 28, 2026, an 8-K current report on November 6, 2026 and Form 4 insider filings as recently as November 20, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), GLAUKOS Corp (GKOS) reported revenue of $507.4 million (up 32.3% from FY2024) and a net loss of $187.7 million. Diluted EPS was -$3.28.
  • As of September 30, 2026, 33 institutional investment managers tracked by SignalX reported holding GLAUKOS Corp (GKOS) shares worth $4.3 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by Thurman Alex R. on November 18, 2026 of 2,021 shares at $237.43 per share.
  • In the last 90 days, GKOS insiders reported 0 open-market purchases ($0) and 56 open-market sales ($72.0M) on Form 4, a net sale of $72.0M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$507.4M
+32.3% vs prior year
Insiders · 90 days
0 buys · 56 sells
Net −$72.0M
13F holders
33 funds
$4.3B · −1 vs prior quarter
Latest 8-K
Nov 6, 2026
Item 7.01

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Core business model: Development, manufacturing, and commercialization of ophthalmic surgical implants and pharmaceutical therapies
  • New product emphasis: Commercial launch of iDose TR implant in early 2024 and FDA approval plus planned commercialization of Epioxa pharmaceutical therapy in early 2026
  • Strategic risk exposure: Increased vulnerability to geopolitical conflicts, economic volatility, and supply chain disruptions impacting manufacturing and regulatory processes
  • Quantitative metric: Accumulated deficit of approximately $933.1 million as of December 31, 2025 reflecting ongoing investment and operating losses
  • Noteworthy fact: First-time FDA approval of Epioxa in October 2025, an incision-free keratoconus treatment alternative, marking significant product portfolio expansion

Risk Factors

  • Regulatory risk: U.S. FDA approval of Epioxa in October 2025 requires securing permanent HCPCS J-Code and commercial payer coverage for reimbursement
  • Macroeconomic risk: U.S. tariffs on imports from Canada, Mexico, and China, despite limited exposure, risk escalating trade disputes affecting sourcing costs
  • Supply chain risk: Vendor supply shortages and labor disruptions causing longer lead times and higher raw material costs, impacting gross margins and product availability
  • Competitive risk: Royalty income from Ivantis’ Hydrus Microstent expired April 2025, coinciding with competitor Alcon’s acquisition of Ivantis
  • Financial risk: Accumulated deficit of $933.1 million as of December 31, 2025 with net losses of $187.7 million in 2025, reflecting ongoing unprofitability and high operating expenses

Management Discussion & Analysis

  • Revenue $507.4M, up 32% YoY from $383.5M; US glaucoma sales up 50% to $298.6M, international glaucoma up 18% to $122.5M
  • Gross margin 56% in 2025 vs 75% in 2024; Operating loss $(199.6)M vs $(122.4)M; Net loss $(187.7)M vs $(146.4)M
  • Best segment US glaucoma sales $298.6M (+50%); Worst margin impacted by $112.9M intangible asset impairment, driving cost of sales 139% higher to $224.7M
  • Cash/cash equivalents $90.8M; short-term investments $187.9M; operating cash used $14.8M; investing cash used $77.6M; financing cash provided $11.9M; $80M+ capex planned for Huntsville facility
  • Management expects higher 2026 capex with Huntsville facility construction; key risk in funding operations as cash flows and profitability remain negative

AI summary of the GKOS 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Risk Factors

  • No material changes from June 30, 2026 10-Q, per filing disclosure
  • Regulatory risk: QMSR effective February 2, 2026, replacing FDA Quality System Regulation with ISO 13485:2016 requirements
  • Near-term commercial risk: proposed LCDs from five MACs in May 2026 could impose conditions on iDose TR use
  • Financial risk: accumulated deficit approximately $969.3 million, despite expected liquidity for at least 12 months
  • Operational risk: sole San Clemente campus manufactures nearly all implanted device products, creating disruption concentration

Management Discussion & Analysis

  • Revenue $211.0M, up 58% YoY from $133.5M, led by glaucoma and corneal health products
  • Gross margin 85% vs 78% YoY, with net income $2.0M vs net loss $16.2M
  • Best segment: corneal health revenue $59.0M, up 154% from $23.3M; international glaucoma worst growth, up 13% to $33.4M
  • Cash flow: operating cash provided $40.9M vs $21.6M used YoY; cash, investments and restricted cash $339.8M vs $282.6M
  • Outlook: $42.0M Huntsville Facility project, reimbursement uncertainty for potential iDose TR LCDs, Germany reimbursement challenges

AI summary of the GKOS 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Nov 6, 2026Full analysis →

Item 7.01: Regulation FD Disclosure

  • Investor Presentation intended for recurring discussions with investors and other stakeholders
  • Exhibit 99.1 provides the substantive company disclosures and presentation materials

Item EX-99.1: Item EX-99.1

  • November 2026 investor presentation highlights 14 pipeline programs and 12 commercialized products across glaucoma, cornea, eyelid and retina markets
  • 2025 topline growth 30%, with 10-year revenue CAGR of 20% and $900 million invested in R&D since 2018
Filed Oct 28, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Q3 net sales $211.0M, up 58%, led by Corneal Health growth of 154% and U.S. Glaucoma growth of 47%
  • Gross margin expanded to 85.2% from 78.4%, supporting GAAP operating income of $0.8M versus a $16.4M loss

Item EX-99.2: Item EX-99.2

  • Q3 revenue $211.0M, up 58%, with iDose TR sales approximately $76M and Epioxa sales approximately $53M
  • Non-GAAP operating income $27.3M versus $9.3M loss, signaling operating leverage despite higher commercial and R&D investment

Item 2.02: Results of Operations and Financial Condition

  • Q3 2026 financial results for quarter ended September 30, 2026 announced
  • Press release issued October 28, 2026, with results in Exhibit 99.1

Item 7.01: Regulation FD Disclosure

  • Quarterly Summary covers Glaukos’ third quarter ended September 30, 2026
  • Supplemental business and financial information available in Exhibit 99.2
Filed Aug 3, 2026Full analysis →

Item EX-99.1: Item EX-99.1

  • Investor presentation outlines 13 pipeline programs and 12 commercialized products across glaucoma, cornea, retina and anterior-segment pharmaceuticals
  • 2025 sales grew 30%, with 10-year revenue CAGR of 20% and $900 million invested in R&D since 2018

Item 7.01: Regulation FD Disclosure

  • Investor Presentation covers Glaukos corporate and financial messaging for investor and stakeholder presentations
  • Exhibit 99.1 available through SEC filing and Glaukos investor-relations website

AI summaries of GKOS 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for GKOS

Don't miss the next GKOS filing

  • Alerts as it files. A push when GKOS files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut GKOS, by share count.
  • Ask anything. An AI agent that reads every GKOS filing and answers with sources.

GKOS alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
Thurman Alex R.SellNov 18, 2026$237.43
Thurman Alex R.SellNov 18, 2026$240.24
Thurman Alex R.SellNov 18, 2026$233.62
Thurman Alex R.SellNov 18, 2026$235.50
Thurman Alex R.SellNov 18, 2026$238.26
Thurman Alex R.SellNov 18, 2026$239.52
Thurman Alex R.MNov 18, 2026$45.71
Thurman Alex R.SellNov 18, 2026$232.65

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$383.5M$507.4M
Gross Profit-$289.5M$282.8M
Operating Income--$122.4M-$199.6M
Net Income--$146.4M-$187.7M
Gross Margin-75.5%55.7%
Op. Margin--31.9%-39.3%
Net Margin--38.2%-37.0%
Balance Sheet
Total Assets$940.4M$974.8M$893.5M
Equity$461.8M$766.9M$656.2M
ROE--19.1%-28.6%
Per Share
EPS-$-2.77$-3.28
Cash Flow
Operating CF--$61.3M-$14.8M
CapEx-$6.3M$7.7M

Source: XBRL data in GLAUKOS Corp (GKOS)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate GKOS share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
GKOS shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202633$4.29B
Q2 202634$3.94B
Q1 202633$3.02B
Q4 202529$3.11B
Q3 202531$2.08B
Q2 202528$3.18B
Q1 202527$2.20B
Q4 202424$3.17B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers
New Positions
None this quarter.
Closed Positions

Source: 13F-HR filings on SEC EDGAR (aggregated from 239 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

GKOS filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 20, 2026--
4Nov 20, 2026--
4Nov 19, 2026--
4Nov 18, 2026--
4Nov 16, 2026--
4Nov 16, 2026--
8-KNov 6, 2026Analysis-
4Nov 5, 2026--
4Nov 3, 2026--
4Nov 3, 2026--
4Nov 3, 2026--
8-KOct 28, 2026Analysis-
10-QOct 28, 2026Analysis
4Oct 7, 2026--
4Sep 28, 2026--
4Sep 18, 2026--
4Sep 1, 2026--
4Aug 20, 2026--
4Aug 13, 2026--
4Aug 11, 2026--
8-KAug 3, 2026Analysis-
4Aug 3, 2026--
10-QJul 29, 2026Analysis
8-KJul 29, 2026Analysis-
4Jul 21, 2026--

Related Health Care companies

All Health Care →

GKOS SEC filings: frequently asked questions

Are GKOS insiders buying or selling?

In the last 90 days, GLAUKOS Corp (GKOS) officers, directors and 10% owners reported no open-market purchases and 56 open-market sales worth $72.0 million by 5 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold GKOS stock?

As of September 30, 2026, the largest GLAUKOS Corp (GKOS) holders among the 13F filers tracked by SignalX were BlackRock ($1.5 billion), Vanguard Portfolio Management LLC ($542.5 million), Vanguard Capital Management LLC ($418.2 million), State Street Corp ($379.7 million), Millennium Management ($239.7 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was GKOS's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), GLAUKOS Corp (GKOS) reported revenue of $507.4 million (up 32.3% from FY2024) and a net loss of $187.7 million. Diluted EPS was -$3.28. The figures come from the XBRL data in the 10-K.

What are the main risks in GKOS's latest 10-K?

In the 10-K filed February 23, 2026, GLAUKOS Corp (GKOS) flagged: Regulatory risk: U.S. FDA approval of Epioxa in October 2025 requires securing permanent HCPCS J-Code and commercial payer coverage for reimbursement. Macroeconomic risk: U.S. tariffs on imports from Canada, Mexico, and China, despite limited exposure, risk escalating trade disputes affecting sourcing costs. (AI summary of the Risk Factors section.)

What did GKOS report in its latest 8-K?

GLAUKOS Corp (GKOS) filed an 8-K on November 6, 2026 reporting Item 7.01 (Regulation FD Disclosure). Investor Presentation intended for recurring discussions with investors and other stakeholders.

What are the latest GKOS SEC filings?

GLAUKOS Corp (GKOS) filed its latest 10-K annual report on February 23, 2026, a 10-Q quarterly report on October 28, 2026, an 8-K current report on November 6, 2026 and a Form 4 insider filing on November 20, 2026.

What is GKOS's SEC CIK number?

GLAUKOS Corp (GKOS)'s SEC Central Index Key (CIK) is 1192448. EDGAR lists every GKOS filing under that number.

Ask anything about GKOS

The research agent reads GKOS's filings, financials, insider trades and 13F holders, then answers with sources.